Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer.

IF 1.3 Q4 SUBSTANCE ABUSE
Journal of Smoking Cessation Pub Date : 2018-12-01 Epub Date: 2017-12-11 DOI:10.1017/jsc.2017.24
Krysten W Bold, Benjamin A Toll, Brenda Cartmel, Bennie B Ford, Alana M Rojewski, Ralitza Gueorguieva, Stephanie S O'Malley, Lisa M Fucito
{"title":"Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer.","authors":"Krysten W Bold,&nbsp;Benjamin A Toll,&nbsp;Brenda Cartmel,&nbsp;Bennie B Ford,&nbsp;Alana M Rojewski,&nbsp;Ralitza Gueorguieva,&nbsp;Stephanie S O'Malley,&nbsp;Lisa M Fucito","doi":"10.1017/jsc.2017.24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lung cancer screening and tobacco treatment for patients at high-risk for lung cancer may greatly reduce mortality from smoking, and there is an urgent need to improve smoking cessation therapies for this population.</p><p><strong>Aims: </strong>The purpose of this study is to test the efficacy of two separate, sequential interventions to promote tobacco cessation/reduction compared to standard care in smokers considered high-risk for lung cancer.</p><p><strong>Methods: </strong>The study will recruit 276 current smokers attending a lung cancer screening clinic or considered high-risk for lung cancer based on age and smoking history across two sites. Patients first will be randomized to either standard tobacco treatment (8 weeks of nicotine patch and five individual counselling sessions) or standard tobacco treatment plus personalized gain-framed messaging. At the 8-week visit, all patients will be re-randomized to receive biomarker feedback or no biomarker feedback. Repeated assessments during treatment will be used to evaluate changes in novel biomarkers: skin carotenoids, lung function, and plasma bilirubin that will be used for biomarker feedback. We hypothesize that personalized gain-framed messages and receiving biomarker feedback related to tobacco cessation/reduction will improve quit rates and prevent relapse compared to standard care. Primary outcomes include 7-day point-prevalence abstinence verified with expired carbon monoxide at 8 weeks and mean cigarettes per day in the past week at 6 months.</p><p><strong>Conclusions: </strong>Study findings will inform the development of novel interventions for patients at risk for lung cancer to improve smoking cessation rates.</p>","PeriodicalId":39350,"journal":{"name":"Journal of Smoking Cessation","volume":"13 4","pages":"244-247"},"PeriodicalIF":1.3000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/jsc.2017.24","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Smoking Cessation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/jsc.2017.24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/12/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 4

Abstract

Background: Lung cancer screening and tobacco treatment for patients at high-risk for lung cancer may greatly reduce mortality from smoking, and there is an urgent need to improve smoking cessation therapies for this population.

Aims: The purpose of this study is to test the efficacy of two separate, sequential interventions to promote tobacco cessation/reduction compared to standard care in smokers considered high-risk for lung cancer.

Methods: The study will recruit 276 current smokers attending a lung cancer screening clinic or considered high-risk for lung cancer based on age and smoking history across two sites. Patients first will be randomized to either standard tobacco treatment (8 weeks of nicotine patch and five individual counselling sessions) or standard tobacco treatment plus personalized gain-framed messaging. At the 8-week visit, all patients will be re-randomized to receive biomarker feedback or no biomarker feedback. Repeated assessments during treatment will be used to evaluate changes in novel biomarkers: skin carotenoids, lung function, and plasma bilirubin that will be used for biomarker feedback. We hypothesize that personalized gain-framed messages and receiving biomarker feedback related to tobacco cessation/reduction will improve quit rates and prevent relapse compared to standard care. Primary outcomes include 7-day point-prevalence abstinence verified with expired carbon monoxide at 8 weeks and mean cigarettes per day in the past week at 6 months.

Conclusions: Study findings will inform the development of novel interventions for patients at risk for lung cancer to improve smoking cessation rates.

Abstract Image

个性化干预方案:烟草治疗肺癌高危患者。
背景:肺癌高危患者的肺癌筛查和烟草治疗可以大大降低吸烟死亡率,迫切需要改善这一人群的戒烟治疗。目的:本研究的目的是测试两种独立的、顺序的干预措施的效果,以促进戒烟/减少与标准治疗相比,被认为是肺癌高风险的吸烟者。方法:该研究将招募276名目前在肺癌筛查诊所或根据年龄和吸烟史被认为是肺癌高危人群的吸烟者。首先,患者将随机接受标准烟草治疗(8周尼古丁贴片和5次个人咨询会议)或标准烟草治疗加上个性化的增益框架信息。在8周的随访中,所有患者将被重新随机分组,接受生物标志物反馈或没有生物标志物反馈。治疗期间的重复评估将用于评估新的生物标志物的变化:皮肤类胡萝卜素、肺功能和血浆胆红素,这些将用于生物标志物反馈。我们假设,与标准治疗相比,个性化的增益框架信息和接收与戒烟/减少相关的生物标志物反馈将提高戒烟率并防止复发。主要结果包括7天的点流行性戒烟,在8周时通过一氧化碳过期验证,在6个月时过去一周平均每天吸烟。结论:研究结果将为肺癌高危患者开发新的干预措施以提高戒烟率提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Smoking Cessation
Journal of Smoking Cessation Medicine-Psychiatry and Mental Health
CiteScore
1.70
自引率
0.00%
发文量
13
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信